close :

:

Forgotten your password?
 
FDA Drug Approvals
Printable Version   Email to a friend

Vaccinia DynPort Vaccine Company LLC - Treatment for Complications of Smallpox Vaccination

Vaccinia Immune Globulin Intravenous (VIGIV) is the first intravenous human plasma-derived product available to treat certain rare complications of smallpox vaccination.

Related Articles:

DVC Announces FDA Acceptance for Filing of Vaccinia Immune Globulin BLA - August 3, 2004

Latest FDA Drug Approvals...

FDA Drug Approvals Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Oct | Dec

More News Resources